2023 saw key developments in the biotech industry, with notable breakthroughs in Alzheimer’s disease treatments, obesity management, and cancer therapy. There were also significant strides in artificial intelligence (AI) and mRNA technology. Key highlights include FDA’s approval of the Alzheimer’s treatment, LEQEMBI, developed by Eisai Co. and Biogen Inc., advancements in obesity treatments such as GLP-1 analogues, and gene therapies, the approval of world’s first CRISPR-based therapy, Casgevy, by the UK, and AI-powered drug repurposing.

‘Cyber incident’ continues to disrupt computer networks at some Sudbury-area schools – CTV News
Several schools in the Sudbury area continue to face disruptions in their computer networks due to an ongoing cyber incident. This has caused challenges for